FDA Brief

Warning letters Drugs

FDA warning letter to

Soda Pharm

High riskIssued Mar 10, 2022Posted Mar 11, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned Soda Pharm over selling unapproved herbal products with COVID-19 treatment and prevention claims online.

What happened

FDA reviewed sodapharmlife.com on February 7, 2022, and FTC reviewed it March 8, 2022, along with Facebook and Instagram pages. The sites offered products such as Cold/Flu/COVID Pack, teas, extracts, syrups, Vapor Balm, and Mustard Plaster with claims they could manage, prevent, or treat COVID-19. FDA called the products unapproved new drugs and misbranded drugs.

What FDA found

  1. The products are unapproved new drugs because they are intended to treat, prevent, diagnose, or cure COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs, meaning their labeling violates drug labeling rules.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company introduced or delivered these products for introduction into interstate commerce, which is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that its products can prevent, treat, or cure disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. The company made deceptive COVID-19 treatment, cure, prevention, or mitigation claims that are subject to civil penalties.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA tells the company to take immediate action to stop selling unapproved products for COVID-19 and to email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours with the steps taken and documentation to prevent recurrence. If it cannot correct the matter within 48 hours, it must state the reason and when it will.

Who should pay attention

  • online sellers of herbal remedies and supplements
  • companies making COVID-19 health claims
  • social media marketers promoting disease treatments

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk